Skip to content
type1.science

Omnipod GO (pump)

Insulet

A first-of-its-kind basal-only tubeless pod: a small waterproof patch that delivers a single fixed daily dose of rapid-acting insulin for up to 72 hours, with no controller, app, phone or CGM. FDA-cleared in 2023 for adults with type 2 diabetes on long-acting injections — not indicated for type 1 diabetes.

Available nowRegulator-approvedpumptubelesspatch

The scorecard

Interoperability4

Deliberately standalone: it connects to no CGM, no AID algorithm, no DIY loop and no phone — a closed, single-purpose basal device by design.

Reliability68

Built on Insulet's mature, waterproof Pod platform with automated cannula insertion and an occlusion hazard alarm (~3-5 U missed); fixed-rate delivery is simple, but it shares single-use Pods' occasional early-failure risk and has a far smaller track record than Omnipod 5.

Form factor92

Fully tubeless, waterproof patch (IP28, ~7.6 m/60 min) worn directly on the body — the category's convenience benchmark, with no tubing and no handheld to carry.

Phone control2

No phone, app or controller of any kind — and no bolus capability; the daily dose is fixed at the factory and cannot be adjusted by the user.

Capacity50

Holds up to 200 U of U-100 insulin (min 85 U fill) over ~72 h wear, but the usable fixed daily dose is capped at 10-40 U/day across seven preset Pods, and the whole Pod is discarded each change.

Access & cost40

US-only, requiring HCP training via a sample kit and a new prescription to change dose; rolled out in a limited pilot from 2023 with broader commercialization in 2024, and it carries ongoing single-use Pod cost.

The full picture

The Omnipod GO is the simplest member of the Omnipod hardware family: a tubeless patch pod that delivers one fixed daily dose of rapid-acting insulin and nothing else. It was FDA-cleared in April 2023 for adults (18+) with type 2 diabetes who would otherwise take daily long-acting (basal) injections — it is not indicated for type 1 diabetes, so its direct T1D relevance is limited; it is documented here for completeness of the Omnipod family.12

Form factor: a tubeless patch, no tubing. Like its Omnipod siblings it is a small, self-contained, waterproof pod worn directly on the skin, with no tubing and no separate insulin line.13 It is built on the same Pod platform as Omnipod DASH/5, which is waterproof to IP28 (up to ~7.6 m / 25 ft for 60 minutes) and inserts its cannula automatically.45

Reservoir, cannula and wear. Each Pod is filled with U-100 rapid-acting insulin (the shared Pod holds up to 200 units, with a minimum fill of about 85 units) and worn for up to 72 hours (3 days) before being replaced as a whole single-use unit.52 A small flexible cannula is inserted automatically when the Pod is activated by snapping off a hard plastic tab — after filling, the Pod prepares to insert roughly 3 minutes after an amber light appears, so it must be on the skin before then.6

The defining limitation: a fixed daily rate, no bolus. The Omnipod GO delivers a fixed, continuous basal rate only. It comes in seven pre-programmed daily rates from 10 to 40 units per day; the rate is set at manufacture and cannot be adjusted by the user.12 To change the dose, a clinician prescribes a different preset Pod — there is no on-device programming, and there is no mealtime bolus function at all.6

No controller, no phone, no CGM, no AID, no DIY. Uniquely among insulin pumps, the Omnipod GO operates without any handheld controller, app or smartphone.12 It does not connect to a continuous glucose monitor, does not run or pair with any automated-insulin-delivery (AID) algorithm, and does not work with DIY/open-source loops — it is a standalone, single-function basal device.13 Getting started requires a healthcare provider to train the user with an Omnipod GO Sample Kit.6

Occlusion detection and reliability. It shares the Insulet Pod's safety mechanics, including automated cannula insertion and a hazard alarm that sounds when an occlusion (a blockage averaging roughly 3-5 units of missed insulin) is detected.65 The underlying Pod hardware has a long real-world track record across the Omnipod line, though the GO itself is far newer and narrower in use.4

Compatible insulins. It is cleared for U-100 NovoLog, Fiasp, Humalog, Admelog and Lyumjev.12

Access and cost. Omnipod GO is a US-only product. Insulet launched it in a limited US pilot from 2023, with broader commercialization in 2024; there is no UK or EU availability.32 As with all Pods, the trade-off for having no durable hardware is the ongoing cost of single-use Pods, and access requires HCP training plus a prescription tied to the specific daily rate.6

What's coming. The Omnipod GO occupies the entry rung of Insulet's type 2 strategy. Insulet has separately expanded the full-featured Omnipod 5 to adults with type 2 diabetes, and has announced a fully closed-loop type 2 system (no carb counting required) targeting a 2028 launch — initially for people on both basal and mealtime insulin, later expanding to basal-only users; its Evolution 2 feasibility study has completed enrollment with a pivotal trial planned to start in 2026.7 For people with type 1 diabetes, the GO is a dead end by design, but it signals Insulet's intent to bring on-body delivery to the much larger basal-insulin population.7

References

  1. Insulet Corporation. Insulet Announces FDA Clearance of Omnipod GO, a First-of-its-Kind Basal-Only Insulin Pod, Further Simplifying Life for People with Type 2 Diabetes. Insulet investor news (Apr 25, 2023; T2D adults 18+, fixed rate, seven preset daily rates 10-40 U/day, 72 h wear, tubeless/waterproof, no handheld controller, U-100 insulins). https://investors.insulet.com/news/news-details/2023/Insulet-Announces-FDA-Clearance-of-Omnipod-GO-a-First-of-its-Kind-Basal-Only-Insulin-Pod-Further-Simplifying-Life-for-People-with-Type-2-Diabetes/default.aspx ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  2. Insulet Corporation. FDA Clearance of Omnipod GO — basal-only insulin pod (BusinessWire press release, Apr 25, 2023; designed for the >3 million people using basal insulin or transitioning to insulin therapy for type 2 diabetes; planned US commercialization 2024). https://www.businesswire.com/news/home/20230424006026/en/Insulet-Announces-FDA-Clearance-of-Omnipod-GO-a-First-of-its-Kind-Basal-Only-Insulin-Pod-Further-Simplifying-Life-for-People-with-Type-2-Diabetes ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  3. Drug Delivery Business News. FDA clears basal-only insulin pod for type 2 diabetes from Insulet (Apr 2023; standalone tubeless waterproof pod, fixed rate, no handheld device, US pilot/2024 commercialization). https://www.drugdeliverybusiness.com/fda-clears-basal-insulin-pod-insulet-diabetes/ ↩ ↩2 ↩3

  4. Ly TT, Layne JE, Huyett LM, Nazzaro D, O'Connor JB. Novel Bluetooth-Enabled Tubeless Insulin Pump: Innovating Pump Therapy for Patients in the Digital Age. J Diabetes Sci Technol (2018); 13(1):20-26. According to PubMed (shared Insulet Pod platform: tubeless waterproof IP28 housing, up to 200 U U-100, automated cannula insertion). https://pmc.ncbi.nlm.nih.gov/articles/PMC6313290/ (DOI) ↩ ↩2

  5. Insulet (Omnipod). Omnipod GO Insulin Delivery Device — Quick Start Guide (US English) (Pod fill 85-200 U U-100, ~72 h wear, automated cannula, IP28 waterproofing, occlusion hazard alarm). https://www.omnipod.com/sites/default/files/GO_Quick_Start_Guide_US_English.pdf ↩ ↩2 ↩3

  6. Insulet (Omnipod). Omnipod GO Frequently Asked Questions (fixed preset daily rate not user-adjustable; HCP changes prescription to change dose; activation by snapping off the tab with ~3-minute insertion window; HCP training via Omnipod GO Sample Kit; occlusion alarm at ~3-5 U missed). https://www.omnipod.com/current-podders/resources/omnipod-go/faqs ↩ ↩2 ↩3 ↩4 ↩5

  7. MedTech Dive. Insulet unveils plans for new diabetes devices (Omnipod 5 expanded to type 2; planned fully closed-loop type 2 system in 2028, no carb counting, initially basal+bolus users then basal-only; Evolution 2 study enrollment complete, pivotal trial planned 2026). https://www.medtechdive.com/news/insulet-patch-pump-plans/806292/ ↩ ↩2

What's next for this

  • →Insulet fully closed-loop type 2 system (no carb counting); Evolution 2 feasibility enrollment complete, pivotal trial planned to start 2026 · launch targeting 2028
  • →Omnipod 5 expanded to adults with type 2 diabetes